February 2nd, 2023 DelveInsight Business Research LLP Releases
DelveInsight’s ‘HER2 Negative Breast Cancer Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline HER2 Negative Breast Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the HER2 Negative Breast Cancer pipeline domain.
For HER2 Negative Breast Cancer emerging drugs, the HER2 Negative Breast Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the HER2 Negative Breast Cancer Pipeline Report
Request a sample and discover the recent breakthroughs happening in the HER2 Negative Breast Cancer pipeline landscape @ HER2 Negative Breast Cancer Pipeline Outlook
HER2 Negative Breast Cancer Overview
The majority of breast cancers express the estrogen receptor (ER) and are negative for the human epidermal growth factor receptor 2 (HER2). ER+/HER2 -ve Breast Cancer refers to tumors that are ER-positive and PR-positive but HER2-negative. ER+/HER2 – positive breast cancer is diverse and accounts for approximately 70% of all breast cancers. HER2 is an abbreviation for human epidermal growth factor receptor 2. Some types of breast cancer have hormone receptors such as estrogen or progesterone (or both) and are referred to as ER+ or PR+ breast cancer.
Find out more about HER2 Negative Breast Cancer medication @ New Drugs for HER2 Negative Breast Cancer
HER2 Negative Breast Cancer Pipeline Analysis: Drug Profile
Capivasertib (AZD5363) is a highly selective oral inhibitor of the serine/threonine kinase AKT. Capivasertib in combination with fulvestrant is currently being studied in phase III clinical trials for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer who have recurred or progressed on or after aromatase inhibitor (AI) therapy.
Dalpiciclib (SHR 6390) is an orally administered small molecule that inhibits cyclin-dependent kinase (CDK)-4/6. Dalpiciclib is being tested in Phase III clinical trials with Letrozole, Anastrozole, or Fulvestrant in patients with HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer.
HER2 Negative Breast Cancer Pipeline Therapies and Key Companies
Learn more about the novel and emerging HER2 Negative Breast Cancer pipeline therapies @ HER2 Negative Breast Cancer Clinical Trials
HER2 Negative Breast Cancer Therapeutics Assessment
Scope of the HER2 Negative Breast Cancer Pipeline Report
Dive deep into rich insights for drugs used for HER2 Negative Breast Cancer treatment; visit @ HER2 Negative Breast Cancer Drugs
For further information on the HER2 Negative Breast Cancer therapy in the pipeline, reach out @ HER2 Negative Breast Cancer Medication
HER2-Positive Breast Cancer Market
HER2-Positive Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2-positive breast cancer companies, including Shanghai Henlius Biotech, Roche Pharma AG, GeneQuantum Healthcare (Suzhou) Co., Ltd., Klus Pharma Inc., Carisma Therapeutics Inc, among others.
HER2-Positive Breast Cancer Epidemiology
HER2-Positive Breast Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted HER2-positive breast cancer epidemiology in the 7MM.
HER2-Positive Early Breast Cancer Pipeline
HER2-Positive Early Breast Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2-positive early breast cancer companies, including Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, DualityBio Inc., Seagen Inc., among others.
HER2-Positive Early Breast Cancer Market
HER2-Positive Early Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2-positive early breast cancer companies, including Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, DualityBio Inc., Seagen Inc., among others.
HER2-Negative Breast Cancer Market
HER2-Negative Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2-negative breast cancer companies, including Sanofi, BeiGene, AstraZeneca, Radius Pharmaceuticals, Novartis, Amgen, among others.
Goitre Market | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Thyroid Cancer Market | Hemostasis Market | Peptic Ulcers Market
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve .
Connect With Us at LinkedIn | Facebook | Twitter
Sign up and submit a press release
Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.